TGFB1 and cancer: Interestingly, we observed a positive correlation between IFGRNS scores and the signatures of resistance to anti‐PD‐1 immunotherapy (Hugo IPRES, Chakravarthy TGF‐β‐associated ECM, Peng TIDE signature, Joseph ISG.RS, and Mariathasan pan‐fibroblast TGF‐β signature) while a negative correlation was observed with responsiveness signatures (Ayers IFN‐γ signature, TIDE dysfunction, and Riaz nivolumab responsive signature) (Figure 6A) in several cancer types.